The feasibility of plerixafor as a second-line stem cell mobilizing agent in children.
Aabideen
Kanakkande
K
Department of Pediatric Hemato-Oncology, Royal Marsden Hospital NHS Foundation Trust, Sutton, UK. abidcmc@yahoo.com
Anoop
Parameswaran
P
Ethell
Mark E
ME
Potter
Mike N
MN
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001596:Benzylamines; D002648:Child; D002675:Child, Preschool; D000080027:Cyclams; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006571:Heterocyclic Compounds / Q000627:therapeutic use*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008297:Male; D008527:Medulloblastoma / Q000188:drug therapy*; D009367:Neoplasm Staging; D009396:Wilms Tumor / Q000188:drug therapy*
D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; C088327:plerixafor